Disc Medicine, Inc. Cash and Restricted Cash
Disc Medicine, Inc. (IRON) had Cash and Restricted Cash of $98.92 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $98.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.16M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91.39M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $140.90M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $98.92M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $89.16M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $91.39M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $140.90M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $127.58M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $122.91M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $192.67M 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $192.87M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $280.90M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $342.85M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $360.62M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $370.66M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $377.72M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $236.60M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $194.79M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $55.65M 10-Q · filed 2023-11-09 | $101.74M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $65.34M 10-Q · filed 2023-08-11 | $108.66M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $74.47M 10-Q · filed 2023-05-15 | $119.39M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $88.21M 10-K · filed 2024-03-21 | $136.95M 10-K · filed 2022-03-10 |
| 2021-09-30 | $150.39M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $167.80M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $185.31M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $25.89M 10-K · filed 2023-03-31 | $4.83M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $13.54M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $6.50M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $13.52M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $3.31M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |